The NADPARK Study: A Randomized Phase I Trial of Nicotinamide Riboside Supplementation in Parkinson’s Disease

Objective

To assess the safety, tolerability, and cerebral penetration of NR therapy in Parkinson’s disease (PD) patients, as well as determine if NR has an impact on their neurometabolic profile and motor symptoms.

Study Design

Randomized, double-blind, placebo-controlled, phase I study in 30 PD patients

Dose

1000 mg

Duration

30 days

Key Outcomes

  • NR supplementation significantly increased cerebral NAD+ levels, altered brain metabolic pattern, and decreased levels of inflammatory cytokines in the cerebrospinal fluid of PD patients.

  • Moreover, patients experienced a mild but significant clinical improvement, and this correlated with the change in the brain’s metabolic pattern.

Clinical, Neurological HealthANAD StaffParkinson's Disease, Neurological Health